Your browser version may not work well with NCBI's Web applications. More information
here...
-
Novel factor Xa inhibitors based on a 2-carboxyindole scaffold: SAR of P4 substituents in combination with a neutral P1 ligand.
Nazaré M,
Essrich M,
Will DW,
Matter H,
Ritter K,
Urmann M,
Bauer A,
Schreuder H,
Czech J,
Lorenz M,
Laux V,
Wehner V.
Aventis Pharma Deutschland GmbH, D-65926 Frankfurt am Main, Germany. marc.navarre@aventis.com
A series of novel, highly potent 2-carboxyindole-based factor Xa inhibitors is described. Structural requirements for P4 ligands in combination with a neutral biaryl P1 ligand were investigated with the 2-carboxyindole scaffold. A diverse set of P4 substituents was identified, which, in conjunction with a biaryl P1 ligand, gave highly potent factor Xa inhibitors, which were also selective versus other proteases and efficacious in various antithrombotic secondary assays.
PMID: 15261269 [PubMed - indexed for MEDLINE]
-
Related Articles